Asfotase Alfa

CHEMBL2108311 Phase 4 Approved Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

A recombinant enzyme replacement therapy that provides the alkaline phosphatase activity absent or severely reduced in patients with hypophosphatasia, a rare inherited disorder causing weak bones. It is given by subcutaneous injection.

Mechanism of Action

Provides exogenous replacement of the deficient enzyme, restoring the metabolic pathway and clearing accumulated substrates from affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanism

Provides exogenous replacement of the deficient enzyme, restoring the metabolic pathway and clearing accumulated substrates from affected tissues.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

A recombinant enzyme replacement therapy that provides the alkaline phosphatase activity absent or severely reduced in patients with hypophosphatasia, a rare inherited disorder causing weak bones. It is given by subcutaneous injection.

Provides exogenous replacement of the deficient enzyme, restoring the metabolic pathway and clearing accumulated substrates from affected tissues.

Yes, Asfotase Alfa is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108311. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.